English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Bacillus Calmette–Guérin (BCG), the only approved tuberculosis vaccine, provides only limited protection. Previously, we generated a recombinant derivative (BCG Δ ureC :: hly ), which secretes the pore-forming toxin listeriolysin O (LLO) of  Listeria monocytogenes . This vaccine shows superior protection against tuberculosis in preclinical models and is safe in humans. Here we describe two new vaccine strains which express human interleukin-7 (hIL)-7 or hIL-18 in the genetic background of BCG Δ ureC :: hly  to modulate specific T cell immunity. Both strains exhibited an uncompromised  in vitro  growth pattern, while inducing a proinflammatory cytokine profile in human dendritic cells (DCs). Human DCs harbouring either strain efficiently promoted secretion of IL-2 by autologous T cells in a coculture system, suggesting superior immunogenicity. BALB/c mice vaccinated with BCG Δ ureC :: hly , BCG Δ ureC :: hly_hIL7  or BCG Δ ureC :: hly _ hIL18  developed a more robust Th1 response than after vaccination with parental BCG. Both strains provided significantly better protection than BCG in a murine  Mycobacterium tuberculosis  challenge model but efficacy remained comparable to that afforded by BCG Δ ureC :: hly . We conclude that expression of hIL-7 or hIL-18 enhanced specific T cell responses but failed to improve protection over BCG Δ ureC :: hly  in mice.

plos one

The Tuberculosis Vaccine Candidate Bacillus Calmette-Guérin ΔureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice